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Objectives This study investigated whether defibrillation threshold (DFT) testing during implantable cardioverter-defibrillator
(ICD) implantation predicts clinical outcomes.
Background Defibrillation testing is often performed during insertion of ICDs to confirm shock efficacy. There are no prospec-
tive data to suggest that this procedure improves outcomes when modern ICDs are implanted for primary pre-
vention of sudden death.
Methods The analysis included the 811 patients who were randomized to the ICD arm of the SCD-HeFT (Sudden Cardiac
Death in Heart Failure Trial) and had the device implanted. The DFT testing protocol in SCD-HeFT was designed
to limit shock testing in a primary prevention heart failure population.
Results Baseline DFT data were available for 717 patients (88.4%). All 717 patients had a DFT of 30 J, the maximum
output of the device in this study. The DFT was 20 J in 97.8% of patients. There was no survival difference be-
tween patients with a lower DFT (10 J, n  547) and a higher DFT (10 J, n  170) (p  0.41). First shock
efficacy was 83.0% for the first clinical ventricular tachyarrhythmia event; there were no differences in shock
efficacies when the cohort was subdivided by baseline DFT.
Conclusions Low baseline DFTs were obtained in patients with stable, optimally treated heart failure during ICD implantation
for primary prevention of sudden death. First shock efficacy for ventricular tachyarrhythmias was high regardless
of baseline DFT testing results. Baseline DFT testing did not predict long-term mortality or shock efficacy in this
study. (J Am Coll Cardiol 2008;52:551–6) © 2008 by the American College of Cardiology Foundation
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The SCD-HeFT DFT Testing and Outcomes August 12, 2008:551–6Implantable cardioverter-defibril-
lators (ICDs) have been shown
to reduce mortality when used
for primary prevention of sudden
cardiac death (SCD). This ben-
efit has been shown in patients
with reduced systolic function
caused by both ischemic (1,2)
and nonischemic cardiomyopa-
thies (2).
Electrical defibrillation of ven-
tricular tachyarrhythmias is a
probabilistic event in both ani-
mal and human studies, espe-
ially at the margin of efficacy (3,4). Increased defibrillation
nergy generally results in a greater chance of success, a
elationship expressed with a sinusoidal curve. The defibril-
ation threshold (DFT) has been defined variously, either as
he amount of energy required to defibrillate 50% of induced
See page 557
entricular fibrillation (VF) episodes (5) or as the lowest
mount of energy required to defibrillate (6). Because of the
otentially catastrophic nature of defibrillation failure, phy-
icians implanting ICDs often attempt to demonstrate the
fficacy of the device by inducing VF and determining the
FT or by performing limited shock testing to determine a
ufficient safety margin. Some investigators have advocated
or “shock-free” DFT testing to determine the upper limit
f vulnerability as an alternative to inducing VF (7). These
ractices originate from an earlier era in ICD technology
hen defibrillation with monophasic waveforms and less
ffective electrode systems were more of a challenge. Mod-
rn ICDs defibrillate effectively as a result of optimally
tructured biphasic shock waveforms that use an active can
lectrode system (8–11). Neither DFT testing nor upper
imit of vulnerability testing has been definitively linked to
mproved outcomes in a prospective trial using current
echnology.
Most primary prevention ICD trials (1,2) included some
ype of DFT testing as part of the ICD procedural protocol,
lthough specific DFT testing protocols have not been well
escribed. Although current literature generally recom-
ends DFT testing, evidence for this practice is minimal
6,12). Limited prospective data are available from a single
enter using monophasic waveform technology in a small
ohort, and thus it is unclear whether these data can be used
o justify the practice of DFT testing with modern devices
13). More recent publications continue to advocate DFT
esting, but these studies failed to show increased mortality
n those with an inadequate DFT safety margin (14–16).
oreover, additional surgical procedures required to im-
rove DFTs, such as ICD generator repositioning, lead
Abbreviations
and Acronyms
DFT  defibrillation
threshold
EGM  electrogram
ICD  implantable
cardioverter-defibrillator
SCD  sudden cardiac
death
VF  ventricular fibrillation
VT  ventricular
tachycardiaepositioning, or subcutaneous array placement in addition to extensive shock testing, may carry more risk to the patient
han the laboratory finding of an increased DFT. In a recent
eview (17), DFT testing was noted as the “legal standard of
are,” but the investigators suggest that testing is clearly
ndicated and safe in 45% of ICD recipients, is contraindi-
ated in 5%, and neither its safety nor indication is clear in
he remaining 50%. Published guidelines do not officially
ecommend DFT testing (18), and the Centers for Medi-
are and Medicaid Services make no specific recommenda-
ions for or against testing (19).
The SCD-HeFT (Sudden Cardiac Death in Heart Fail-
re Trial) is the largest and longest-duration randomized,
rospective, primary prevention trial in both ischemic and
onischemic heart failure patients to date. The DFT testing
rotocol in this trial called for only minimal shock testing; ICD
mplantation was recommended regardless of the outcome.
he purpose of the present study is to examine the relationship
etween DFT testing results and clinical outcomes.
ethods
he SCD-HeFT methods and results have been described
n detail elsewhere (2,20). The SCD-HeFT study was a
ational Institutes of Health-sponsored multicenter clinical
rial in which 2,521 patients without a history of sustained
entricular tachycardia (VT) or cardiac arrest were randomly
ssigned in equal proportions to receive an ICD, amioda-
one, or placebo. The enrolled patients had chronic mod-
rate heart failure (New York Heart Association functional
lass II or III) and a left ventricular ejection fraction 35%.
he study protocol required optimal medical therapy with
ngiotensin-converting enzyme inhibitor or angiotensin-
eceptor antagonist, beta-receptor antagonist, and aldosterone-
ntagonist drugs as prescribed by current heart failure guide-
ines before randomization. Outpatient ICD implantation
as recommended.
The ICDs implanted in SCD-HeFT were intentionally
imited to single-lead devices because patients with indica-
ions for dual-chamber pacing were excluded by protocol.
ost patients (94%) received a Medtronic Micro Jewel II
odel 7223 device (Minneapolis, Minnesota), whereas the
emaining 6% received another Medtronic single-lead device.
aximum device output was 30 J. No biventricular devices
ere permitted at implantation. The ICD was uniformly
rogrammed with a detection rate of 188 beats/min. Ther-
py was programmed to a single tachyarrhythmia zone, shock-
nly mode. No antitachycardia pacing was permitted to min-
mize the potential for accelerating tachyarrhythmias or for
reating nonsustained ventricular tachycardia in patients who
ere not known to have VT. Bradycardia pacing was set to 50
eats/min with a hysteresis of 34 beats/min.
The SCD-HeFT DFT testing protocol sought to mini-
ize the number of VF inductions to balance the risk of
esting against perceived benefit in a population that had, at
he time of trial enrollment, no known indication for ICD
herapy. The VF was induced with a T-wave shock (21).
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August 12, 2008:551–6 The SCD-HeFT DFT Testing and Outcomesfter detection of VF, the first defibrillation shock of 20 J
as delivered. If unsuccessful, a transthoracic rescue shock
as applied. A 5-min rest period was recommended be-
ween VF inductions. If the first defibrillation attempt at 20 J
as successful, the second defibrillation attempt was to be
erformed with a 10-J shock. If the first attempt of 20 J was
nsuccessful, the second attempt was to be performed with
30-J shock. No further VF inductions were recommended
egardless of defibrillation success after the second induc-
ion. In this trial, the DFT was defined as the lowest
uccessful shock output. The ICD therapy was programmed
ith the first shock set 10 J over the DFT (if 20 J)
ollowed by maximum output shocks for all remaining
herapies. The shock waveform was programmed bipolar
ith the right ventricular coil anodal (BAX) for therapies
through 4 with reversed polarity for therapies 5 and 6. The
CD was implanted regardless of DFT testing results, and
he use of alternative lead systems or devices was strongly
iscouraged to minimize risk and to preserve the uniformity
f the study protocol.
The ICD data were routinely downloaded at 3-month
ollow-up visits and after known ICD therapy. Post-
ortem ICD interrogation was recommended after all
atient deaths. The ICD electrogram (EGM) data were
ent electronically to the ICD EGM core laboratory. Two
embers of the ICD EGM Committee independently
eviewed each shock episode and categorized each rhythm
efore and after each shock according to pre-specified
riteria (22). Rhythms were categorized based on data from
oth R-R interval plots and EGM recordings, when avail-
ble. The EGM Committee was blinded to patient outcome
nd all clinical data. Disagreements were adjudicated by the
ull EGM Committee.
Only the first appropriate shock experienced by a patient
or VF or VT was considered in this analysis. This was
hosen by study design, because baseline DFT testing was
onsidered to most likely relate to a first arrhythmic event
ather than subsequent events, in which events such as
rogressive heart failure, ischemia, the potential adverse
ffect of recurrent shocks, or new antiarrhythmic therapy
ould be confounding factors. Shock success was defined as
ermination of the detected VF or VT, as determined by
ntracardiac post-shock EGM recording, and not by clinical
utcome. This analysis includes only those patients who had
T or VF events detected with the SCD-HeFT–specified
rogramming protocol. Arrhythmia events detected only
ecause of protocol deviation with a second zone of therapy
rogrammed with antitachycardia pacing are not included
ecause of the unknown effects of delaying shock therapy
ue to pacing interventions.
tatistical analysis. Overall cumulative survival was ana-
yzed with the Kaplan-Meier method after arbitrarily divid-
ng the ICD cohort into low and high DFT groups (23).
urvival between the 2 groups was compared using a Cox
egression model (24). Covariates included in this model
ere age, gender, heart failure etiology, New York Heart hssociation functional class, time since heart failure diag-
osis, ejection fraction, 6-min walk distance, systolic blood
ressure, diabetes, angiotensin-converting enzyme inhibitor
se, digoxin use, mitral valve regurgitation, renal insuffi-
iency, substance abuse, baseline electrocardiographic inter-
als, and the Duke Activity Status Index (25). There are no
ublished data available to estimate the mortality benefit, if
ny, that DFT testing provides. However, assuming an
lpha of 0.05 (2-sided), we would have 80% power for
etecting a 38% difference in mortality between groups with
he 146 deaths in our cohort.
A sensitivity analysis was performed to account for
atients without baseline DFT testing data available by
ncluding this group first in the high-DFT group, followed
y including them in the low-DFT group and repeating the
nalyses.
We tested for association between baseline DFT testing
esults and defibrillation success for spontaneous VF or VT
pisodes, using the Fisher exact test (26). A p value of
0.05 was considered significant. For all analyses, commer-
ially available statistical package software was used (SAS
ersion 8.2, SAS Institute Inc., Cary, North Carolina, and
PSS version 11.5, SPSS, Inc., Chicago, Illinois). Patients
ho had their ICD explanted were included in the ICD
roup for analysis in an intention-to-treat manner.
The investigators had full access to the data and take
esponsibility for its integrity. All investigators have read
nd agree to the article as written.
esults
aseline ICD implantation and DFT data. Of the 2,521
atients enrolled in the SCD-HeFT, 829 were randomized
o the ICD arm. Of those, 17 patients refused ICD
mplantation and 1 patient died before implantation. There-
ore, 811 patients were included in this study. The median
ollow-up for all surviving patients was 45.5 months. All
urviving patients were followed up for at least 2 years, and
ital status was known for all patients at the time of last
ollow-up. Of those with an ICD implanted, 31 (3.8%) had
heir ICD removed and not replaced during follow-up because
f device complications (n  8), other medical problems (n 
), or heart transplantation (n  20).
Baseline DFT testing data were available from 717
atients (88.4% of those with an ICD). Of the remaining 94
atients, no data were received by the ICD event core
aboratory for 88 patients and ICD testing was intentionally
ot performed in 6 cases. Of the 717 patients, most had
FT testing performed according to protocol, although 26
3.6%) had testing performed at additional energy levels. All
f the 717 patients were defibrillated at 30 J and 97.8%
ad successful defibrillation at 20 J (Fig. 1).
Patients with a DFT of 10 J all had their first shock
nergy programmed to 30 J. Patients with a DFT of 10 J
ad the first shock programmed to 20 J (86.8%) or 30 J
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The SCD-HeFT DFT Testing and Outcomes August 12, 2008:551–613.2%), the latter because of investigator-elected protocol
eviation.
urvival associated with baseline DFT results. The pa-
ients were divided into a low-DFT group (10 J) and a
igh-DFT group (10 J). There were 113 deaths in the
ow-DFT group (overall mortality 20.7%) and 33 deaths in
he high-DFT group (overall mortality 19.4%.) After ad-
usting for baseline prognostic variables, there was no
ifference in overall survival between the 2 groups (hazard
atio [HR] for DFT 10: 1.19; 95% confidence interval
CI]: 0.72 to 1.58, p  0.41) (Fig. 2). The results were not
ltered, regardless of whether the 94 patients with missing
ata were considered in the high-DFT or low-DFT group,
p  0.75 and p  0.13, respectively).
hock efficacy and baseline DFT result. Of the 811 ICD
atients, 182 (22.4%) experienced at least 1 ICD-detected
pisode of VT or VF during follow-up. The first shock
elivered during the first occurrence of either VF or VT
whichever came first in patients with recurrent events) was
uccessful in 151 of these patients (83.0%). The relationship
etween first shock efficacy was similarly high regardless of
hether patients had a baseline DFT of10 J,11 to20
, or20 J. There was no significant difference between first
hock efficacy rates in these groups (82.6%, 81.0%, and
00% respectively, p  0.88) (Table 1). Patients without
aseline DFT testing data had a first shock efficacy of
0.4%, which was not significantly different from those with
FT data available (p  0.13).
hythm outcome in first shock failures. Unsuccessful
hocks were analyzed to determine the eventual rhythm
Figure 1 Histogram of Baseline DFT
Data at the Time of ICD Implantation
DFT  defibrillation threshold; ICD  implantable cardioverter-defibrillator.utcome. Of 31 patients with an unsuccessful first shock, in Dnly 3 patients did all subsequent shocks fail; these 3
atients are known to have died on the day of the ICD-
etected rhythm. The remaining 28 patients are known to
ave survived this event. In 6 of these 28 cases, the rhythm
elf-terminated after the first failed shock. In 8 more cases,
second or third shock was successful. In the remaining 14
ases, the arrhythmia fell below the detection rate and no
urther EGM data were recorded; presumably, these ar-
hythmias self-terminated given that clinical outcome
ollow-up showed that these patients were alive after the
vent.
iscussion
he present study represents the only prospective analysis of
he relationship between DFT testing and outcomes in
atients treated with modern ICDs. There are several
ignificant findings. First, in a primary prevention ICD
atient population treated with good heart failure medical
herapy, implant defibrillation efficacy for induced VF was
ell within the accepted safety margin for the vast majority
f patients. Second, the first shock success for spontaneous
T or VF events was good (80%) regardless of implant
mplant DFTs, Appropriate Shocks, and Efficacy:irst Shock Efficacy for he First VT or VF Eventccording to Baseline DFT
Table 1
Implant DFTs, Appropriate Shocks, and Efficacy:
First Shock Efficacy for the First VT or VF Event
According to Baseline DFT
Implant DFT
Patients With an
Appropriate Shock
First Appropriate Shock
Success Rate (Efficacy)
10 J (n  547) 134 82.6%
11–20 J (n  154) 24 81.0%
21–30 J (n  16) 3 100%
Unknown (n  94) 21 90.4%
Figure 2 Kaplan-Meier Survival Curves
Curves show no difference in all-cause mortality when patients with an ICD
were divided by high-DFT and low-DFT groups (hazard ratio for DFT 10: 1.19;
95% confidence interval: 0.72 to 1.58; p  0.41). Abbreviations as in Figure 1.FT  defibrillation threshold; VF  ventricular fibrillation; VT  ventricular tachycardia.
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August 12, 2008:551–6 The SCD-HeFT DFT Testing and OutcomesFT. Finally, survival after a first appropriate VT or VF
vent was similarly high for patients with high or low
aseline DFT testing.
Of the failed shocks analyzed here, 9.7% were followed
mmediately by death. These occurred in hospitalized pa-
ients who had significant clinical deterioration in their
ardiac status. The ICDs do not completely eliminate the
isk of sudden death, particularly in those with progressive
eart failure, but most failed shocks did not result in death.
here are data to suggest that many shock failures occur in
he setting of electrical–mechanical dissociation (27), a
henomenon not likely to be related to baseline DFT
esting.
It is remarkable that all patients for whom data were
vailable had successful implant defibrillation for induced
F of 30 J. This may reflect a stable outpatient cohort of
atients appropriately treated with good heart failure med-
cations. Therefore, our results may not be applicable to a
ore ill patient population. It is often in the more ill patient
hat the adverse effects of VF induction are considered a
eason not to perform testing. That DFT testing may be
rrelevant to successful ICD treatment of spontaneous VT
r VF may justify a paradigm shift in the traditional
pproach to these patients. Although we observed first
hock failure in approximately 20% of patients, this was only
atal in 3 patients, all of whom were hospitalized at the time
or progressive heart failure. Our study cannot make specific
ecommendations for patients who are found to have an
mplant DFT of greater than the output of the device,
lthough our data suggest that there will be a very small
umber of such patients in this study population. It is
nteresting to note that the 3 patients who had an appro-
riate shock for VT or VF and had no DFT safety margin
i.e., a DFT of 30 J) during ICD implantation, had 100%
ffective shocks, again questioning the utility of DFT
esting in this population.
Shock efficacy must also take into consideration the
ritical components of ICD technology and shock delivery.
hock energy alone is known to be a very poor surrogate for
efibrillation efficacy, and many features of waveform design
i.e., capacitance, phase duration, waveform tilt, peak volt-
ge, and peak current levels) as well as electrode design and
ocation (e.g., material, French size, location, and ICD
urface area) can influence defibrillation (6). Early studies of
efibrillation evaluating these components have resulted in
odern-day devices that are highly efficient at delivering
hock energy. As a consequence, the findings of this study
ay not necessarily extend to other ICDs with significantly
ifferent energy delivery systems.
tudy limitations. This study has several limitations. First,
ot all data on implant testing were available to the ICD
vent core laboratory. Whether the data were not immedi-
tely sent and therefore were overwritten or were never
aved at all is not known. Second, because few patients had
 high DFT, conclusions regarding the outcomes of patients
ithout the usual DFT safety margin cannot be made.hird, defibrillation testing for induced VF may not predict
ardioversion efficacy for ventricular tachycardia. In this
tudy, only 71 of the 182 patients (39.0%) with an appro-
riate shock had VF. Differences may exist between VF and
T; however, because of small numbers, statistical analysis
f these subgroups was not performed. Comparing out-
omes at implant testing for induced VF with that of
pontaneous VT may be fundamentally limiting. Finally,
he relatively small number of deaths in our cohort reduces
ur ability to detect small changes in survival related to DFT
esting.
onclusions
his study presents unique data supporting a limited ap-
roach to DFT testing in stable outpatients with New York
eart Association functional class II or III heart failure.
ur results challenge the commonly accepted requirement
o perform routine DFT testing during ICD implantation
or primary prevention of sudden cardiac death. Given the
ack of correlation between baseline DFT testing and either
hock efficacy or survival, future studies should determine
hether DFT testing in this population should be aban-
oned altogether.
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